Connect your AI

GeneDx Holdings WGS Short-term warrant liability

Other financials

Income statement

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

Market cap$1.89B-24.3%

Enterprise value$1.89B-22.8%

P/S4.3×-3.3×

Profitability

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept wgs:WarrantLiabilityCurrent.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's short-term warrant liability.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is GeneDx Holdings's short-term warrant liability?: GeneDx Holdings (WGS) reported short-term warrant liability of $220K in Q1 2026.